BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market

BD (NYSE:BDX) and Ypsomed are expanding their collaboration to develop a 5.5 mL BD Neopak™ XtraFlow™ glass prefillable syringe compatible with Ypsomed's YpsoMate® 5.5 autoinjector to support large‑volume, high‑viscosity subcutaneous biologics.

Rhea-AI Summary

BD (NYSE:BDX) and Ypsomed are expanding their collaboration to develop a 5.5 mL BD Neopak™ XtraFlow™ glass prefillable syringe compatible with Ypsomed's YpsoMate® 5.5 autoinjector to support large‑volume, high‑viscosity subcutaneous biologics. The syringe uses an 8 mm needle and thinner cannulas to improve flow and reduce injection time. Syringe samples for feasibility studies and YpsoMate 5.5 platform updates are expected in mid‑2026.

Positive

• New 5.5 mL syringe expands large‑volume self‑injection options
• Design uses 8 mm needle and thinner cannulas to improve flow
• Syringe samples for feasibility studies expected in mid‑2026
• Builds on proven 2.25 mL pairing that supported viscosities up to 70 cP

Negative

• Product is still in development and not yet commercially available
• Compatibility and performance depend on future testing and validation
• No regulatory approvals or commercial launch dates disclosed

Argus Jan 21 session

+1.37% close to close Open Argus

Details

News Market Reaction – BDX

On Jan 21, the day this news came out, BDX closed 1.37% above the previous close.

Data tracked by StockTitan Argus for the Jan 21 session.

Market Context

This announcement reinforces BD’s focus on high-dose biologics and self-injection by extending the N...

Analysis

This announcement reinforces BD’s focus on high-dose biologics and self-injection by extending the Neopak XtraFlow platform to a 5.5 mL syringe compatible with Ypsomed’s YpsoMate 5.5 autoinjector. It builds on prior success with the 2.25 mL format and targets higher-volume, higher-viscosity therapies. Investors can track progress toward mid‑2026 feasibility samples and integration, alongside BD’s broader investments in Neopak syringe manufacturing and biologics-focused infrastructure.

Key Figures

Syringe volume: 5.5 mL Needle length: 8 millimeters Large-volume threshold: greater than 1 mL +5 more

Syringe volume

5.5 mL

BD Neopak XtraFlow Glass Prefillable Syringe version for YpsoMate 5.5

Needle length

8 millimeters

Shorter needle design for higher volume and viscosity medicines

Large-volume threshold

greater than 1 mL

Definition of large-volume subcutaneous biologic injections

Legacy syringe volume

2.25 mL

BD Neopak XtraFlow 2.25mL Glass Prefillable Syringe in prior combo

Viscosity reference

up to 70 cP

Prior combination demonstrated performance up to 70cP viscosities

Platform launch year

2022

YpsoMate 5.5 autoinjector platform introduction

Sample availability

mid-2026

Feasibility study syringe samples expected timing

Integration timeline

mid-2026

Ypsomed plans to integrate BD 5.5mL syringe into YpsoMate 5.5

Historical Context

5 past events · Latest: Jan 15

5 events

1. Jan 15

   Regulatory clearance

   24h Move

   +0.5%

   FDA 510(k) clearance for EnCor EnCompass breast biopsy system.

2. Jan 14

   Management change

   24h Move

   +2.9%

   Appointment of new senior vice president of investor relations.

3. Jan 13

   Capacity investment

   24h Move

   -0.6%

   $110M investment to expand Neopak syringe and cannula production.

4. Jan 12

   Shareholder meeting

   24h Move

   -0.6%

   Announcement of virtual 2026 annual meeting logistics.

5. Jan 05

   Clinical milestone

   24h Move

   +2.1%

   First Phasix hernia prevention case in Greece and PREVENT trial progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

subcutaneous, autoinjector, biologics, cannulas

4 terms

subcutaneous medical

"Large‑volume (greater than 1 mL) subcutaneous injections of biologics are increasingly common"

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

autoinjector medical

"compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform, expanding options"

A prefilled, spring‑loaded medical device that automatically delivers a measured dose of medication beneath the skin when pressed against the body, like a self‑operating syringe packaged for quick use. Investors care because autoinjectors can increase patient safety, adherence and convenience — factors that drive demand, shape reimbursement and regulatory review, and affect a product’s market size, manufacturing complexity and competitive moat.

biologics medical

"partnership to address rapidly growing biologics market"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

cannulas medical

"including a shorter, 8-millimeter needle and thinner wall cannulas, to support"

A cannula is a small, tube-like medical device inserted into the body to deliver or remove fluids, gases or medications—think of it as a straw or pipe doctors use to move liquids or oxygen in and out safely. Investors watch cannula markets because demand, pricing, safety records and regulatory approvals affect hospital purchasing, device makers’ revenues and profit margins, and can signal broader trends in medical procedures and supply chains.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The enhanced collaboration and innovation will improve options for pharmaceutical companies and patients requiring large-volume self-injection systems

LE PONT-DE-CLAIX, France and BURGDORF, Switzerland, Jan. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe. This innovation is designed to be fully compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform, expanding options for pharmaceutical companies and patients who require large‑volume subcutaneous self‑injections.

Meeting the Needs of Today and Tomorrow's Biologics

The new 5.5mL BD Neopak™ XtraFlow™ Glass Prefillable Syringe leverages BD advanced technologies, including a shorter, 8-millimeter needle and thinner wall cannulas, to support the delivery of higher volume and viscosity medicines. These enhancements should enable improved injection time and optimized flow, addressing common challenges with large-volume biologics and enabling drug developers to move beyond the limitations of standard syringe offerings.

"This next generation syringe is a direct response to the growing demand for patient-friendly solutions in the high-dose biologics space," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "By combining BD's expertise in drug delivery with Ypsomed's leadership in autoinjector platforms, we are helping to simplify self-injection for patients managing complex conditions."

Supporting Innovation in Self-Administration

Large‑volume (greater than 1 mL) subcutaneous injections of biologics are increasingly common in areas such as oncology, autoimmune diseases, rare diseases, and metabolic disorders. Ypsomed's YpsoMate® 5.5, introduced in 2022, was developed to meet this need, offering an ergonomic design, intuitive two‑step activation, and clear feedback to support patient confidence and ease of use.

The new BD Neopak™ XtraFlow™ 5.5mL Glass Prefillable Syringe is designed to further enhance the YpsoMate® 5.5 platform by maximizing flow efficiency and reducing injection time*, which are critical factors as dosing volumes and drug viscosities continue to rise.

"Ypsomed and BD, in close collaboration with our pharmaceutical partners, are expanding the subcutaneous delivery design space to accommodate high-dose therapies, both volume and viscosity," said Ulrike Bauer, Chief Business Officer at Ypsomed. "These partnerships are critical as we jointly drive the future of high-dose biopharmaceutical delivery."

A Proven Partnership for Better Patient Outcomes

BD and Ypsomed have a strong history of collaboration, beginning with the BD Neopak™ XtraFlow™ 2.25mL Glass Prefillable Syringe and YpsoMate® 2.25 autoinjector. This combination demonstrated improved flow and optimized injection times across a range of drug viscosities, including up to 70cP¹. The new 5.5 mL version builds on this success, aiming to accelerate and de-risk development of combination products and reduce time-to-market for pharmaceutical companies.

Looking Ahead

The BD Neopak™ XtraFlow™ 5.5mL Glass Prefillable Syringe is currently in development and will undergo comprehensive testing to ensure compatibility with the YpsoMate® 5.5 platform. Syringe samples for feasibility studies are expected to be available in mid-2026. Within the same timeline, Ypsomed will expand the YpsoMate 5.5 platform and integrate the BD Neopak™ XtraFlow™ 5.5mL Glass Prefillable Syringe.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Ypsomed Group  
Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.

www.ypsomed.com

Contacts:

Media:                                                                                        Investors:

Fallon McLoughlin                                                                     Adam Reiffe
Director, Public Relations                                                          VP, Investor Relations
201.258.0361                                                                            201.847.6927        
fallon.mcloughlin@bd.com                                                        adam.reiffe@bd.com     

Ypsomed Holding AG Media & Investor Relations:
Susanne Köhler
Head of Public Relations
+41 34 424 47 32
susanne.koehler@ypsomed.com   

*When compared to 12.7 mm special thin wall needle

1. Blaser, T. & Douaire, M. (May 20, 2025). Optimising High‑Dose Delivery: Syringe–Autoinjector Integration, Injection Time and Performance. ONdrugDelivery, Issue 172, pp. 32–37

The BD Neopak™ XtraFlow™ 5.5mL Glass Prefillable Syringe is a product in development. Some statements are forward-looking and are subject to a variety of risks and uncertainties.

BD, the BD Logo, Neopak, and XtraFlow are trademarks of Becton, Dickinson and Company or its affiliates. © 2026 BD. All rights reserved.

All other trademarks are the property of their respective owners.

YpsoMate is a registered trademark of Ypsomed AG.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-ypsomed-expand-partnership-to-address-rapidly-growing-biologics-market-302665913.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the BD and Ypsomed 5.5 mL syringe announcement for BDX on January 21, 2026?

BD and Ypsomed announced development of a 5.5 mL BD Neopak XtraFlow glass syringe compatible with Ypsomed's YpsoMate 5.5 autoinjector to support large‑volume biologics.

When will BD Neopak XtraFlow 5.5 mL syringe samples be available for feasibility studies?

Syringe samples for feasibility studies are expected to be available in mid‑2026.

How does the 5.5 mL BD Neopak XtraFlow syringe improve injections for high‑dose biologics (BDX)?

The design uses a shorter 8 mm needle and thinner cannulas to maximize flow and reduce injection time for higher volumes and viscosities.

Is the BD Neopak XtraFlow 5.5 mL syringe currently approved for commercial use (BDX)?

No; the syringe is in development and will undergo comprehensive testing before any commercial availability.

Will Ypsomed update the YpsoMate 5.5 autoinjector to integrate the BD 5.5 mL syringe?

Yes; Ypsomed plans to expand the YpsoMate 5.5 platform and integrate the BD Neopak XtraFlow 5.5 mL syringe within the mid‑2026 timeline.